MoonLake Immunotherapeutics (MLTX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
DORFSTRASSE 29 ZUG, 6300 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 511,008,237 | 72,114,735 | 666,790 | 1,335,924 | |||
| Cash and cash equivalents | 451,169,337 | 39,505,627 | 666,790 | 1,335,924 | |||
| Short-term investments | 59,838,900 | 32,609,108 | |||||
| Receivables | 1,056,862 | 217,129 | |||||
| Prepaid expense | 2,102,203 | 4,179,468 | 126,916 | 283,057 | |||
| Total current assets: | 514,167,302 | 76,511,332 | 793,706 | 1,618,981 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 3,628,480 | 282,580 | |||||
| Property, plant and equipment | 320,865 | 49,389 | |||||
| Prepaid expense | 8,423,468 | ||||||
| Asset, held-in-trust | 115,042,608 | 115,014,917 | |||||
| Total noncurrent assets: | 12,372,813 | 331,969 | 115,042,608 | 115,014,917 | |||
| TOTAL ASSETS: | 526,540,115 | 76,843,301 | 115,836,314 | 116,633,898 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 3,520,966 | 1,284,676 | 3,870,251 | 67,120 | |||
| Accounts payable | 264,522 | 65,116 | |||||
| Accrued liabilities | 3,256,444 | 1,219,560 | 3,870,251 | 67,120 | |||
| Debt | 58,063 | ||||||
| Other undisclosed current liabilities | 6,444,714 | 6,380,770 | |||||
| Total current liabilities: | 9,965,680 | 7,665,446 | 3,870,251 | 125,183 | |||
| Noncurrent Liabilities | |||||||
| Liabilities, other than long-term debt | 3,083,416 | 411,157 | 4,025,000 | 4,025,000 | |||
| Deferred compensation liability, classified | 4,025,000 | 4,025,000 | |||||
| Liability, pension and other postretirement and postemployment benefits | 583,426 | 282,206 | |||||
| Operating lease, liability | 2,499,990 | 128,951 | |||||
| Total noncurrent liabilities: | 3,083,416 | 411,157 | 4,025,000 | 4,025,000 | |||
| Total liabilities: | 13,049,096 | 8,076,603 | 7,895,251 | 4,150,183 | |||
| Temporary equity, carrying amount | 115,000,000 | 115,000,000 | |||||
| Equity | |||||||
| Equity, attributable to parent, including: | 495,675,683 | 48,898,296 | (7,058,937) | (2,516,285) | |||
| Common stock | 43 | 43 | |||||
| Additional paid in capital | 609,969,236 | 129,192,291 | |||||
| Accumulated other comprehensive income | 2,357,621 | 350,946 | |||||
| Accumulated deficit | (116,657,472) | (80,650,212) | (7,059,268) | (2,516,616) | |||
| Other undisclosed equity, attributable to parent | 6,298 | 5,271 | 288 | 288 | |||
| Equity, attributable to noncontrolling interest | 17,815,336 | 19,868,402 | |||||
| Total equity: | 513,491,019 | 68,766,698 | (7,058,937) | (2,516,285) | |||
| TOTAL LIABILITIES AND EQUITY: | 526,540,115 | 76,843,301 | 115,836,314 | 116,633,898 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Operating expenses | (54,123,096) | (65,061,417) | (4,570,345) | |||
| Operating loss: | (54,123,096) | (65,061,417) | (4,570,345) | |||
| Nonoperating income | 10,289,860 | 917,049 | 27,691 | |||
| Investment income, nonoperating | 27,691 | |||||
| Gain, foreign currency transaction, before tax | 151,493 | 325,317 | ||||
| Other nonoperating income | 10,138,367 | 591,732 | ||||
| Loss from continuing operations before equity method investments, income taxes: | (43,833,236) | (64,144,368) | (4,542,654) | |||
| Other undisclosed loss from continuing operations before income taxes | (151,493) | (325,317) | ||||
| Loss from continuing operations before income taxes: | (43,984,729) | (64,469,685) | (4,542,654) | |||
| Income tax expense | (94,388) | (36,366) | ||||
| Loss from continuing operations: | (44,079,117) | (64,506,051) | (4,542,654) | |||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (4,542,654) | ✕ | |
| Net loss: | (44,079,117) | (64,506,051) | (4,542,654) | |||
| Net income attributable to noncontrolling interest | 8,071,857 | 14,532,802 | 4,542,654 | |||
| Other undisclosed net loss attributable to parent | (4,542,654) | |||||
| Net loss available to common stockholders, diluted: | (36,007,260) | (49,973,249) | (4,542,654) | |||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|
| Net loss: | (44,079,117) | (64,506,051) | (4,542,654) | |||
| Other comprehensive income (loss) | 1,993,522 | 660,646 | ||||
| Comprehensive loss: | (42,085,595) | (63,845,405) | (4,542,654) | |||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 7,573,872 | 14,407,944 | 4,542,654 | |||
| Comprehensive loss, net of tax, attributable to parent: | (34,511,723) | (49,437,461) | ||||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.